<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02252094</url>
  </required_header>
  <id_info>
    <org_study_id>NMRC/TA/0015/2013</org_study_id>
    <nct_id>NCT02252094</nct_id>
  </id_info>
  <brief_title>Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS</brief_title>
  <acronym>U-Protect</acronym>
  <official_title>Ultra-protective Pulmonary Ventilation Supported by Low Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) and Prone Positioning for ARDS; a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Health System, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Health System, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of ultra-protective ventilation, where very low ventilation
      volumes are used, in patients with severe acute respiratory distress syndrome (ARDS) meeting
      criteria to nurse in the prone position. Half the patients will receive ultra-protective
      ventilation support by extracorporeal carbon dioxide removal, while the other half will
      receive conventional lung protective ventilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current best practices for management of severe ARDS include lung protective ventilation and
      nursing in the prone position. However, the best lung protective strategy is not currently
      established and using smaller ventilation volumes than standard lung protective ventilation
      suggest lung recovery is improved.

      Application of smaller ventilation volumes requires extracorporeal carbon dioxide removal,
      using a device similar to a dialysis to remove carbon dioxide directly from the blood. One
      such device in the Prismalung, it removes blood through a catheter, much like a dialysis
      catheter, pumps it through a gas exchange cartridge which removes carbon dioxide. The gas
      exchange cartridge functions in a similar way to a dialysis filter, except it allow gases to
      pass through, unlike dialysis filters which allow passage of fluid and small molecules.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Data analysis will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plateau Pressure</measure>
    <time_frame>Duration of ventilation for severe ARDS, expected average time 10 days</time_frame>
    <description>Ability to achieve a plateau pressure of &lt;/=25 cmH20 in the intervention arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU stay</measure>
    <time_frame>Duration of patient stay in ICU, expected average stay 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Duration of patient stay in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Monitored for 3 months</time_frame>
    <description>ICU mortality, hospital mortality, 30 day, 60 day and 90 day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Imaging</measure>
    <time_frame>One data set per patient during first 72 hours</time_frame>
    <description>Echocardiogram data will be collected before prone position, after prone positioning and following initiation of ultra-protective ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracorporeal carbon dioxide removal related complications</measure>
    <time_frame>Duration of severe ARDS, expected average time frame 10 days</time_frame>
    <description>Complications or adverse events related to ECCO2R and associated anticoagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All severe adverse events</measure>
    <time_frame>Duration of ICU stay (anticipate average stay 1-2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient meeting proning criteria in each group</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to successfully prone</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dialysis in ICU, and ability to successfully initiate</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of referrals for ECMO</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and reasons for declining consent to study participation</measure>
    <time_frame>First 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enrolment rates</measure>
    <time_frame>First 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung recruitability</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation parameters</measure>
    <time_frame>Duration of mechanical ventilation</time_frame>
    <description>Data download from mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator associated pneumonia rates</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barotrauma complications</measure>
    <time_frame>Duration of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Pulmonary Inflammation</measure>
    <time_frame>Day 0, 4 and 7</time_frame>
    <description>Serum will be drawn and stored for pulmonary biomarkers analysis at the above time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Conventional lung protective ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra-protective ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultra-protective ventilation (&lt;/= 3ml/kg predicted body weight) targeting plateau pressure of &lt;/= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prismalung</intervention_name>
    <description>Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.</description>
    <arm_group_label>Ultra-protective ventilation</arm_group_label>
    <other_name>Low flow extracorporeal carbon dioxide removal</other_name>
    <other_name>Respiratory Dialysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultra-protective ventilation</intervention_name>
    <description>Ventilation with &lt;/= 3ml/kg predicted body weight</description>
    <arm_group_label>Ultra-protective ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Lung Protective Ventilation</intervention_name>
    <description>Ventilation with 6ml/kg predicted body weight</description>
    <arm_group_label>Conventional lung protective ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to MICU with respiratory failure and intubated

          -  ARDS criteria per Berlin definition

          -  PaO2:FiO2 ratio ≤ 200 mmHg for &gt; 6 hours with FiO2 ≥0.5

          -  Expected to require mechanical ventilation for &gt;48 hours

          -  Reversible disease

        Exclusion Criteria:

          -  Anticoagulation contraindicated

          -  Proven HIT

          -  Unable to obtain central venous access

          -  Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication
             for ECMO

          -  Home oxygen use

          -  Severe COPD

          -  Interstitial lung disease

          -  &gt; 7 days of mechanical ventilation

          -  Immunocompromised patient (bone marrow, untreated HIV, PJP)

          -  Advanced malignancy with life expectancy ≤ 6months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew E Cove, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew E Cove, MBChB</last_name>
    <phone>+65 6772 7678</phone>
    <email>mdcmec@nus.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rinky Puri, MSc</last_name>
    <phone>+65 6779 5555</phone>
    <email>mdcrpp@nus.edu.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Phua, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amartya Mukherjee, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ng Teng Fong General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>609606</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faheem Kahn, MBChB</last_name>
      <phone>6716 2000</phone>
      <email>Faheem_Ahmed_Khan@juronghealth.com.sg</email>
    </contact>
    <contact_backup>
      <last_name>Chee Keat Tan, MBBS</last_name>
      <phone>6716 2000</phone>
      <email>chee_keat_tan@juronghealth.com.sg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano C, Quintel M, Gattinoni L, Ranieri VM. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology. 2009 Oct;111(4):826-35. doi: 10.1097/ALN.0b013e3181b764d2.</citation>
    <PMID>19741487</PMID>
  </reference>
  <reference>
    <citation>Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J, Muellenbach R, Dembinski R, Graf BM, Wewalka M, Philipp A, Wernecke KD, Lubnow M, Slutsky AS. Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med. 2013 May;39(5):847-56. doi: 10.1007/s00134-012-2787-6. Epub 2013 Jan 10.</citation>
    <PMID>23306584</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>May 21, 2017</last_update_submitted>
  <last_update_submitted_qc>May 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University Health System, Singapore</investigator_affiliation>
    <investigator_full_name>Matthew COVE</investigator_full_name>
    <investigator_title>Matthew COVE</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

